Company / Cash & Equivalents
GT Biopharma, Inc. Cash & Equivalents History
FY2011-FY2020 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$5.3M
FY2020
5-year range
$19.0K / $5.3M
FY2016-FY2020
Trend
+27778.9%
vs FY2019
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents changed +27779% YoY in FY2020, a notable deviation from the 7-year average annual change of +4230%.
Based on SEC 10-K filings.
$5M in FY2020 with a 5-year CAGR of +161.9%.
Improved from $855,000 to $5M over the past 4 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +553.3%
- 5-Year CAGR
- +161.9%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +161.9%, indicating consistent growth.
- In FY2020, cash & equivalents increased 27778.9% year-over-year.
- Lowest cash & equivalents in the period was in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2020 | $5.3M | +27778.9% |
| FY2017 | $19.0K | -97.8% |
| FY2016 | $855.0K | +1888.4% |
| FY2015 | $43.0K | +0.0% |
| FY2014 | $43.0K | -65.0% |
| FY2013 | $123.0K | +33.7% |
| FY2012 | $92.0K | +70.4% |
| FY2011 | $54.0K | - |
As of FY2020 · SEC 10-K · Updated Jun 24, 2026